

RESEARCH

Open Access



Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years

Claudio Neidhöfer^{1*}, Esther Sib², Marcel Neuenhoff^{1,3}, Oliver Schwengers³, Tobias Dummin¹, Christian Buechler¹, Niklas Klein^{1,4}, Julian Balks¹, Katharina Axtmann¹, Katjana Schwab⁵, Tobias A. W. Holderried⁵, Georg Feldmann⁵, Peter Brossart⁵, Steffen Engelhart², Nico T. Mutters², Gabriele Bierbaum¹ and Marijo Parčina¹

Abstract

Background Hospitals with their high antimicrobial selection pressure represent the presumably most important reservoir of multidrug-resistant human pathogens. Antibiotics administered in the course of treatment are excreted and discharged into the wastewater system. Not only in patients, but also in the sewers, antimicrobial substances exert selection pressure on existing bacteria and promote the emergence and dissemination of multidrug-resistant clones. In previous studies, two main clusters were identified in all sections of the hospital wastewater network that was investigated, one *K. pneumoniae* ST147 cluster encoding NDM- and OXA-48 carbapenemases and one VIM-encoding *P. aeruginosa* ST823 cluster. In the current study, we investigated if NDM- and OXA-48-encoding *K. pneumoniae* and VIM-encoding *P. aeruginosa* isolates recovered between 2014 and 2021 from oncological patients belonged to those same clusters.

Methods The 32 isolates were re-cultured, whole-genome sequenced, phenotypically tested for their antimicrobial susceptibility, and analyzed for clonality and resistance genes in silico.

Results Among these strains, 25 belonged to the two clusters that had been predominant in the wastewater, while two others belonged to a sequence-type less prominently detected in the drains of the patient rooms.

Conclusion Patients constantly exposed to antibiotics can, in interaction with their persistently antibiotic-exposed sanitary facilities, form a niche that might be supportive for the emergence, the development, the dissemination, and the maintenance of certain nosocomial pathogen populations in the hospital, due to antibiotic-induced selection pressure. Technical and infection control solutions might help preventing transmission of microorganisms from the wastewater system to the patient and vice versa, particularly concerning the shower and toilet drainage. However, a major driving force might also be antibiotic induced selection pressure and parallel antimicrobial stewardship efforts could be essential.

*Correspondence:
Claudio Neidhöfer
claudio.neidhoefer@ukbonn.de
Full list of author information is available at the end of the article



Keywords Multidrug-resistant bacteria, Carbapenemase-encoding bacteria, Antibiotic-resistance, CRKP, CRPsA, *K. pneumoniae* ST147, *P. aeruginosa* ST823, Bacterial colonization, Hospital hygiene, Hospital wastewater

Introduction

Antibiotic resistance is a major global concern, a complex public health issue and is accelerated by improper use of antibiotics as well as a growing population and increased networking and travelling. It depends on many interconnected factors and is far from limited to the clinical setting [1–3]. Resistance is usually acquired through the uptake of resistance genes by bacterial conjugation or other horizontal transmission pathways, spontaneous mutation of genes, upregulation of efflux pumps or intrinsic resistance genes, which subsequently allow the spread of resistant clones by vertical propagation [4]. After administration, antibiotics and their metabolites are released through environmental matrices, such as the sewage system, and exert selection pressure on the bacteria in this environment, favoring the occurrence of the mechanisms described above, multiplying resistance in the environment [1, 5–8]. Among antibiotic-resistant bacteria, carbapenemase-encoding Gram-negative bacteria are currently the most critical microorganisms [9, 10]. Carbapenems are antibiotics of last resort and administered in life-threatening infections caused by Gram-negative bacteria. Because of the large number of high-risk patients in hemato-oncology departments, these only intravenously administered substances are used there to an inordinately high extent, and as a result are released in excessively large quantities into the same sanitary facilities. Such concentrations were found to be in therapeutic concentrations [11, 12]. Because of this massive use of last-resort antibiotics, these highly resistant and critical bacteria are spread primarily through hospital wastewater, as opposed to municipal wastewater or agricultural process water [13]. Furthermore antibiotic resistant bacteria in wastewater are often associated with the ability to form biofilms in which they are able to survive even when confronted with high levels of antibiotics or disinfectants [14].

Klebsiella pneumoniae and *Pseudomonas aeruginosa* are two of the most important opportunistic and nosocomial pathogens worldwide and are known for the ability to produce biofilms to escape treatment with antibiotics [3, 15, 16]. In this study, we compared NDM and OXA-48 encoding *K. pneumoniae* and VIM encoding *P. aeruginosa* isolates recovered from clinical specimens of patients in oncology wards of a tertiary care center to the highly resistant strains that most prominently colonized patient bathrooms or were recovered from different sampling points of the same sewer system. Environmental *K. pneumoniae* ST147 and *P. aeruginosa* ST823 were

analyzed when encoding the mentioned carbapenemases [17]. *K. pneumoniae* ST147 is a well-known high-risk clone that likely emerged in the 1990s and swiftly became a prominent global pathogen [18–20]. Different ST147 clusters are associated with different carbapenemases [18]. On the other hand, *P. aeruginosa* ST823 is mostly associated with *bla*_{VIM} and only few publications exist [21–23]. Reports of this strain in Europe are limited [17, 24].

Methods

Isolates

In the period under study Gram-negative bacterial pathogens recovered from clinical specimens were routinely identified via MALDI-TOF MS (VITEK MS, Biomerieux, Marcy-l'Etoile, France) and susceptibility-tested with the VITEK 2 system (Biomerieux, Marcy-l'Etoile, France). Carbapenem-resistant *K. pneumoniae* and *P. aeruginosa* isolates, or such with an unusual carbapenem-susceptibility profile (ertapenem/imipenem/meropenem) were routinely analyzed for the presence of common resistance genes, using the Allplex Entero-DR Assay (Seegene, Seoul, South Korea).

All VIM-encoding *P. aeruginosa* isolates and all NDM- and OXA-48-encoding *K. pneumoniae* isolates recovered from patients of oncology wards between September 2014 and November 2021 were traced in the laboratory information system, thawed and sub-cultured twice on Columbia 5% sheep blood agar (Becton Dickinson, Heidelberg, Germany) prior to testing and DNA extraction. Only first isolates were selected for each pathogen-patient combination. The environmental strains used for comparison had been isolated between Nov. 2016 and Sept. 2018 [17]

Susceptibility testing

Antimicrobial susceptibility of all isolates after re-cultivation from cryo stocks was determined thrice by broth microdilution. Susceptibility tests were employed strictly according to the manufacturer's instruction. From each isolate, a bacterial suspension in 0.9% saline solution was prepared. The suspension was adjusted to a McFarland value of between 0.48 and 0.52 using a DensiCHEK plus photometer (bioMerieux, Marcy-l'Etoile, France). For broth microdilution, Micronaut-S MDR MRGN-Screening MIC-Plates (Merlin, Bornheim, Germany) were utilized (tested antibiotics are listed in the legend of Table 2

in the “Results” section). Tests were performed with Mueller–Hinton broth (Merlin, Bornheim, Germany) and read with a BioTek ELx808 Absorbance Microplate Reader (now: Agilent Technologies Inc., Santa Clara, CA, USA). MICs were interpreted according to EUCAST 2022 v12 breakpoints (version 01.01.2022) for *Enterobacteriales* and *Pseudomonas*, respectively.

Whole genome sequencing

Highly purified DNA was extracted from all strains using the column-based DNeasy UltraClean Microbial Kit (Qiagen GmbH, Hilden, Germany). The isolation was performed according to the manufacturer’s instructions. Obtained DNA was qualitatively and quantitatively evaluated using the NanoDrop OneC from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Dual-indexed Illumina sequencing libraries were constructed from each sample using the Illumina Nextera XT DNA Library Preparation Kit, pooled, and sequenced on the Illumina MiSeq platform with the Illumina MiSeq Reagent Kit v3, 600 cycles (all three: Illumina, San Diego, CA, USA). All steps were carried out following the manufacturer’s instructions. Raw reads have been uploaded to the Sequence Read Archive (SRA); accession PRJNA845217.

Assembly and genome analysis

Genome assembly and analysis were carried out independently in two different ways. On the one hand, paired-end reads were trimmed and filtered with BBDuk Trimmer with a Q value of 20 and de novo assembled using Geneious Prime (software version 2020.1 Biomatters, Auckland, New Zealand). Analysis of the de novo assembled contigs was then performed with online tools of the CGE-server, ResFinder-4.0 (<https://cge.cbs.dtu.dk/services/ResFinder/>) and PlasmidFinder-2.0 (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) [25–28] and the AMRFinderPlus v3.10.24 (<https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/>) (with its according NCBI reference databases of 04-04-2022 [29]), which were used to identify the presence of antimicrobial resistance genes [30]. In addition to BLASTX, nucleotide sequences were translated into amino-acid sequences to identify corresponding proteins with ALLELEX and EXACTX. Genes with insertions for a stop codon were found with INTERNAL_STOP. POINTN considered strain-specific point mutations and refer to the majority of mentioned stress factors. PARTIALX took gene fragments with incomplete reference sequence into account. The minimum coverage value for PARTIALX was set to 60%. Only results with >90% identity and >90% coverage were accepted. On the other hand, genomes were assembled and analyzed with ASA³P v1.3.0 [31].

Clustering

For epidemiological clustering Ridom SeqSphere+ (version 6.0.2) (Ridom; Münster, Germany) (<http://www.ridom.de/seqsphere>) [32] was used. *K. pneumoniae* sensu lato was employed as cgMLST template for the *K. pneumoniae* strains and the cgMLST template for *P. aeruginosa* was used for the *P. aeruginosa* strains (www.ridom.de/seqsphere/u/Task_Template_Sphere.html). Minimum spanning trees were calculated after ignoring pairwise missing values and after exclusion of genes that were present only in the template strain.

Phylogenetic analysis

Raw sequencing reads for both *K. pneumoniae* and *P. aeruginosa* isolates were processed using ASA³P v1.3.0 [30]. SNP-based maximum-likelihood phylogenetic trees were calculated with FastTree within ASA³P calculating 100 bootstraps using isolates CNK1 and A15448 [17] as reference genomes for the sets, respectively.

All data relevant to the study are included in the article or uploaded as Appendix. The precise source of each environmental sample can be located in the corresponding publication [17]. Environmental samples were collected in approximately equal quantities from drains of sinks, toilets, and showers of hospital rooms in the hemato-oncological ward, from the wastewater of the hemato-oncological clinic, and wastewater sampling locations downstream of it.

The ethics committee of the University Hospital Bonn confirmed that no ethics approval was required for this study.

Results

Isolate and patient information

From September 2014 until November 2021, twenty-two VIM-encoding *P. aeruginosa* isolates and ten NDM- and OXA48-encoding *K. pneumoniae* isolates from patients of the oncology clinic were included into this study. Typing revealed that the majority of *P. aeruginosa* isolates (17) belonged to ST823; two belonged to ST235, another two to ST111, and one to ST233 (see Table 1). All but two *K. pneumoniae* isolates (which belonged to ST78) belonged to ST147. In the majority of patients (18/32), the isolates were first detected after more than four weeks of hospitalization. In half of the patients (16/32), the isolates were obtained from stool samples. All but one, *K. pneumoniae* ST147 isolates, were recovered from the same ward.

Clustering

Fourteen sequenced *P. aeruginosa* ST823 isolates, fell into two different groups as clustering showed (cluster distance threshold was set to 12) when clustered with environmental isolates from 2016 to 2018 from a study

Table 1 General patient information of genotyped VIM-encoding *P. aeruginosa* isolates (CVP) (above) and NDM- and OXA48-encoding *K. pneumoniae* isolates (CNK) (below)

Patient	Age	Year	Ward	LOS	Previously in ICU	Localization	Species	Sequence type	Isolate
1	50–60	2015	A	30	Yes	Stool	<i>P. aeruginosa</i>	823	CVP1
2	60–70	2015	B	13	No	Stool	<i>P. aeruginosa</i>	111	CVP2
3	30–40	2015	B	17	No	Blood	<i>P. aeruginosa</i>	233	CVP3
4	70–80	2015	C	36	–	Skin swab	<i>P. aeruginosa</i>	235	CVP4
5	60–70	2015	C	17	–	BAL	<i>P. aeruginosa</i>	111	CVP5
6	60–70	2016	C	80	–	Urine	<i>P. aeruginosa</i>	823	CVP6
7	50–60	2016	A	2	No	TS	<i>P. aeruginosa</i>	823	CVP7
8	50–60	2016	C	26	–	Stool	<i>P. aeruginosa</i>	823	CVP8
9	20–30	2016	B	48	No	Stool	<i>P. aeruginosa</i>	823	CVP9
10	70–80	2016	A	8	No	Stool	<i>P. aeruginosa</i>	823	CVP10
11	60–70	2016	B	57	No	Stool	<i>P. aeruginosa</i>	823	CVP11
12	50–60	2016	C	17	–	TS	<i>P. aeruginosa</i>	823	CVP12
13	60–70	2017	A	324	Yes	Stool	<i>P. aeruginosa</i>	823	CVP13
14	70–80	2017	A	105	Yes	Stool	<i>P. aeruginosa</i>	823	CVP15
15	60–80	2017	C	101	–	TS	<i>P. aeruginosa</i>	823	CVP16
16	<20	2017	D	180	No	Wound	<i>P. aeruginosa</i>	823	CVP17
17	50–60	2018	B	99	No	Inguinal swab	<i>P. aeruginosa</i>	823	CVP18
18	20–30	2019	A	22	No	Stool	<i>P. aeruginosa</i>	235	CVP19
19	70–80	2020	E	1	No	Anal swab	<i>P. aeruginosa</i>	823	CVP23
20	70–80	2020	D	70	No	Stool	<i>P. aeruginosa</i>	823	CVP24
21	40–50	2021	A	80	No	Stool	<i>P. aeruginosa</i>	823	CVP25
22	60–70	2021	A	104	No	Urine	<i>P. aeruginosa</i>	823	CVP27
23	80–90	2017	B	1	No	Stool	<i>K. pneumoniae</i>	147	CNK1
24	40–50	2017	B	59	Yes	Stool	<i>K. pneumoniae</i>	147	CNK2
25	60–70	2017	C	22	–	Stool	<i>K. pneumoniae</i>	147	CNK3
26	60–70	2017	F	2	No	Urine	<i>K. pneumoniae</i>	78	CNK4
27	50–60	2018	B	12	No	Stool	<i>K. pneumoniae</i>	147	CNK5
28	70–80	2020	B	65	Yes	Wound	<i>K. pneumoniae</i>	147	CNK6
29	70–80	2020	B	1	No	Throat swab	<i>K. pneumoniae</i>	147	CNK7
30	70–80	2021	B	182	No	Stool	<i>K. pneumoniae</i>	147	CNK8
31	50–60	2021	C	65	–	Throat swab	<i>K. pneumoniae</i>	78	CNK9
32	70–80	2021	B	44	Yes	Urine	<i>K. pneumoniae</i>	147	CNK10

LOS: Length of Hospital Stay in days, previous to the date on which the positive sample was collected. Rows are color-coded according to isolate sequence type for better visualization, *P. aeruginosa* ST823 cluster in light blue, *P. aeruginosa* ST235 cluster in purple and *K. pneumoniae* ST147 cluster in red

on hospital drains and wastewater [17] (see Fig. 1). Three out of the four environmental isolates in cluster B, which was the cluster with the predominant number of clinical isolates, had been isolated from the drains of patient rooms. Of the two sequenced *P. aeruginosa*

ST235 isolates, CVP4 did not cluster with environmental isolates but CVP19 was closely related to two environmental isolates (see Fig. 1). All eight sequenced *K. pneumoniae* ST147 isolates were closely related to each other and to the environmental isolates, forming




Fig. 1 VIM-encoding *P. aeruginosa* ST823 cluster in light blue, VIM-encoding *P. aeruginosa* ST235 cluster in purple, and NDM- and OXA48-encoding *K. pneumoniae* ST147 cluster in red, as minimum spanning tree, respectively from top to bottom. The lines and numbers show the number of allele differences between isolates




Fig. 2 SNP-based maximum-Likelihood trees of *K. pneumoniae* ST147 and *P. aeruginosa* ST823 isolates (100 bootstraps). Clinical isolates are marked in light blue and red for *P. aeruginosa* and *K. pneumoniae*, respectively




Fig. 3 Antibiotic resistances profile as predicted by the ASA³P pipeline based on CARD annotations for *P. aeruginosa* ST823 and *K. pneumoniae* ST147 isolates. Colored circles refer to the isolate likely being resistant to the respective substance class, while empty circles refer to the isolate likely being susceptible to it

Table 2 Phenotypical susceptibility of *P. aeruginosa* (above) and *K. pneumoniae* (below) isolates determined by broth microdilution

	CIP	LVX	AMK	CST	CHL	FOF	TGC	SXT	PIP	TZP	CTX	CAZ	CAA	CTA	IPM	MEM	TMO
CVP1	> 2	> 2	32	2	> 16	32	> 4	> 4/76	> 16	16/4	> 2	<= 1	<= 1/4	> 8/4	> 8	32	> 128
CVP2	> 2	> 2	> 32	<= 1	> 16	> 64	> 4	> 4/76	> 16	64/4	> 2	32	16/4	> 8/4	> 8	64	> 128
CVP3	> 2	> 2	> 32	2	> 16	64	> 4	> 4/76	> 16	> 64/4	> 2	64	> 16/4	> 8/4	> 8	> 128	> 128
CVP4	> 2	> 2	<= 4	<= 1	> 16	32	> 4	> 4/76	> 16	> 64/4	> 2	64	> 16/4	> 8/4	> 8	64	> 128
CVP5	> 2	> 2	> 32	<= 1	> 16	> 64	4	> 4/76	> 16	64/4	> 2	16	8/4	> 8/4	> 8	32	> 128
CVP6	> 2	> 2	32	2	> 16	64	> 4	> 4/76	<= 8	8/4	> 2	4	4/4	> 8/4	> 8	16	128
CVP7	> 2	> 2	32	<= 1	> 16	64	2	> 4/76	> 16	8/4	> 2	8	8/4	> 8/4	> 8	32	128
CVP8	> 2	> 2	16	2	> 16	<= 16	> 4	> 4/76	16	8/4	> 2	4	4/4	> 8/4	> 8	64	128
CVP9	> 2	> 2	16	2	> 16	64	> 4	> 4/76	16	16/4	> 2	4	4/4	> 8/4	> 8	16	128
CVP10	> 2	> 2	> 32	<= 1	> 16	<= 16	> 4	> 4/76	> 16	> 64/4	> 2	4	4/4	> 8/4	> 8	128	> 128
CVP11	> 2	> 2	16	<= 1	> 16	32	> 4	> 4/76	> 16	> 64/4	> 2	8	8/4	> 8/4	> 8	32	> 128
CVP12	> 2	> 2	> 32	<= 1	> 16	64	4	> 4/76	> 16	> 16/4	> 2	8	8/4	> 8/4	> 8	16	128
CVP13	> 2	> 2	<= 4	<= 1	> 16	32	2	> 4/76	> 16	64/4	> 2	16	8/4	8/4	> 8	32	> 128
CVP15	> 2	> 2	> 32	2	> 16	64	> 4	> 4/76	16	16/4	> 2	16	16/4	> 8/4	> 8	64	128
CVP16	> 2	> 2	<= 4	<= 1	> 16	<= 16	> 4	> 4/76	> 16	32/4	> 2	8	<= 1/4	<= 1/4	> 8	16	128
CVP17	> 2	> 2	<= 4	<= 1	> 16	64	2	> 4/76	<= 8	8/4	> 2	8	8/4	8/4	> 8	32	128
CVP18	> 2	> 2	32	2	> 16	64	> 4	> 4/76	<= 8	8/4	> 2	4	4/4	> 8/4	> 8	32	128
CVP19	> 2	> 2	> 32	<= 1	> 16	32	> 4	> 4/76	> 16	64/4	> 2	> 128	16/4	> 8/4	> 8	8	128
CVP23	> 2	> 2	> 32	<= 1	> 16	64	2	> 4/76	16	16/4	> 2	16	16/4	> 8/4	> 8	64	128
CVP24	> 2	> 2	32	<= 1	> 16	32	4	> 4/76	> 16	64/4	> 2	32	> 16/4	> 8/4	> 8	> 128	128
CVP25	> 2	> 2	> 32	<= 1	> 16	64	> 4	> 4/76	<= 8	8/4	> 2	4	4/4	> 8/4	> 8	16	128
CVP27	> 2	> 2	> 32	4	> 16	64	> 4	> 4/76	16	8/4	> 2	4	4/4	> 8/4	> 8	32	128
CNK1	> 2	> 2	<= 4	<= 1	<= 8	64	0,5	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	64	> 128
CNK2	> 2	> 2	<= 4	<= 1	<= 8	64	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128
CNK3	> 2	> 2	<= 4	<= 1	<= 8	128	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	4/4	> 8	128	> 128
CNK4	> 2	> 2	> 32	> 8	> 16	32	0,5	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	64	> 128
CNK5	> 2	> 2	<= 4	<= 1	<= 8	128	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128
CNK6	> 2	> 2	8	<= 1	<= 8	64	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	32	> 128
CNK7	> 2	> 2	> 32	> 8	> 16	<= 16	2	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128
CNK8	> 2	> 2	<= 4	> 8	<= 8	32	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128
CNK9	> 2	> 2	<= 4	> 8	<= 8	64	1	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128
CNK10	> 2	> 2	> 32	> 8	> 16	32	0,5	> 4/76	> 16	> 64/4	> 2	> 128	> 16/4	> 8/4	> 8	128	> 128

Isolate cells are colored according to sequence type for better visualization, MIC cells are colored according to isolate susceptibility as per EUCAST 2022 v12 breakpoints (version 01.01, 2022) (green: susceptible, yellow: susceptible at increased dosage, red: resistant)

CIP, ciprofloxacin; LVX, levofloxacin; AMK, amikacin; CST, colistin; CHL, chloramphenicol; FOF, fosfomicin; TGC, tigecycline; SXT, trimetoprim-sulfamethoxazole; PIP, piperacillin; TZP, piperacillin/tazobactam; CTX, cefotaxime; CAZ, ceftazidime; CAA, ceftazidime/avibactam; CTA, ceftolozan/tazobactam; IPM, imipenem; MEM, meropenem; TMO, temocillin

one large cluster. *P. aeruginosa* ST111 and ST233 isolates and *K. pneumoniae* ST78 isolates were not clustered due to the absence of environmental isolates with matching sequence types.

Phylogenetic analysis

As Fig. 2 shows, the isolates within the *K. pneumoniae* ST147 Cluster exhibited a high degree of relatedness to each other, as did the isolates within the *P. aeruginosa* ST823 cluster. Seven out of eight clinical *K. pneumoniae* ST147 isolates belonged to two very small but extremely tight clusters (CNK7 with environmental isolates CU1391, CU1293, CU1470, and CU0050 and CNK1, CNK2, CNK5, CNK6, CNK8 and CNK10 with the environmental isolate CU0071). The *P. aeruginosa* isolates, on the other hand, even more markedly formed one large cluster with the environmental isolates.

Resistance genes

Plasmid incompatibility groups detected in *K. pneumoniae* isolates by PlasmidFinder-2.0 are listed in Table 3 in the appendix. The table shows that several plasmids were shared with environmental ST147 isolates. *K. pneumoniae* ST78 isolates and ST147 isolates did not share any plasmids. All ST147 isolates carried the same plasmids, except for the three latest ST147 isolates, recovered in 2020 and 2021, which carried an additional IncHI2-type plasmid. Tables 4 and 5 in the appendix show the Antibiotic resistance genes detected on VIM-encoding *P. aeruginosa* genomes and on NDM- and OXA48-encoding *K. pneumoniae* genomes by AMRFinderPlus, respectively. There were only two internal stop codons found with INTERNAL_STOP (CVP2 *fosA* and CVP5 *fosA*) in resistance genes. The VIM-encoding gene that was detected in the course of routine diagnostics in CVP19 was not detected on its sequenced genome, but a repeated targeted PCR with the Allplex Entero-DR Assay (Seegene, Seoul, South Korea) from the isolate and its extracted genomic DNA confirmed the presence of the resistance gene. Predicted antibiotic resistances by the ASA³P pipeline for *P. aeruginosa* ST823 and *K. pneumoniae* ST147 isolates are displayed in Fig. 3 in the appendix.

Phenotypical susceptibility

According to EUCAST 2022 v12 breakpoints (version 01.01, 2022) all tested isolates were resistant to fluoroquinolones and imipenem (see Table 2). Despite the metallo-beta-lactamases (MBL), one *P. aeruginosa* isolate (CVP19) was susceptible at high dosing regimen

to meropenem, nine to piperacillin, eleven to piperacillin/tazobactam, and 13 to ceftazidime, as well as 15 at standard dosing regimen to ceftazidime/avibactam. While all *P. aeruginosa* were still susceptible to colistin and 15/22 to ceftazidime/avibactam, 5/10 *K. pneumoniae* isolates were resistant to both. Both *K. pneumoniae* ST78 isolates and the three latest ST147 isolates were resistant to colistin. Analysis of the contigs of the IncHI2-type plasmid showed that it did not carry colistin resistance genes; however, the full sequence of the plasmid was not available for analysis. Among these, two ST147 and one ST78 isolate were also resistant to tigecycline. Two ST147 isolates and one ST78 were resistant to chloramphenicol.

Discussion

K. pneumoniae clones with high AMR risk represent a tremendous public health burden and have played a central role in the global spread of AMR [33]. *K. pneumoniae* ST147 has emerged as one of the most important AMR clones and clearly exhibits most of the essential characteristics that define a global high-risk AMR clone. Several studies have described efficient transmission between patients in the hospital setting [18] and even through drainage water from one room to another [24, 34]. *P. aeruginosa* is increasingly recognized for the ability of certain hospital populations to cause nosocomial infection outbreaks with significant morbidity and mortality. Both, *K. pneumoniae* and *P. aeruginosa*, form biofilms in toilet bowls, particularly behind the flushing rim of the toilet, and establish themselves in hospital water systems, which allow the pathogens to persist and potentially spread out of the toilet each time it is flushed [35, 36]. The two clustering methods exhibited differences in the exact relationships of the isolates, but both demonstrated that even over years, the patient and environmental isolates clustered very closely together, which supports the assumption that these were the same clones [37, 38].

Our study highlights that, consistently antibiotic-exposed patients might, in interaction with their constantly antibiotic-exposed sanitary facilities form a niche that could be supportive for the emergence of certain nosocomial pathogen populations in the hospital, due to antibiotic-induced selection pressure [11, 39]. These highly resistant clones subsequently survive particularly well in the sanitary facilities of those patients who are at highest risk of colonization or infection, i.e., patients who are frequently treated with broad-spectrum antibiotics due to their immunodeficiency, and who have

hardly any remaining healthy normal flora able to out-compete the highly resistant clones [40]. Once colonized, the patients in turn excrete the clones and thus distribute them to other premises and facilities.

In our study, we sequenced two selected sets of carbapenemase-encoding isolates which account only for a fraction of carbapenemase-encoding pathogens encountered in routine practice [41]. While the susceptibility profiles appear atypical for *P. aeruginosa* isolates that encode VIM-type carbapenemases, it should be mentioned that ST823 wastewater isolates exhibited the same kind of antibiograms [17]. Overall, as expected, the therapeutic options were very limited for all isolates [42] with a few newer antibiotics and combinations untested [43]. The effect of the *phoQ* and *pmrB* mutations in the strains is still unclear [44–47]. Prevention, evidently, remains the much more potent means of combating this problem. Since biofilm is one of the most effective ways for bacteria to colonize the aquatic niche of sanitary facilities, its formation should be prevented. Therefore, several preventive hygienic measures were taken according to national recommendations [48]. As constructional measures, toilets in all newly build wards are designed rimless and in high-risk areas toilets were remodeled to fit the rimless standard. As additional routine hygienic measures, surfaces of toilets, sinks and shower basins are daily disinfected chemically, moreover, sink and shower drains are incubated with a solution of oxidizing disinfectants on a weekly basis, in order to minimize biofilm formation and to reduce high microbial burden. In high risk areas (e.g. bone marrow transplantation) disinfection devices on sink drains applying heat and electromechanical vibration [49] had been installed, however, regarding toilets and shower basins there exist no corresponding technical solutions [48]. With the implemented hygiene and prevention measures presumably colonization pressure is decreased due to reduced microbial load of showers and sinks. The present study did not involve an individualized, patient-specific evaluation of transmission routes or a clinical assessment. It is highly probable that all the following transmission routes existed: from patient to environment, from environment

to patient, directly from patient to patient, and through cases that were imported and became detectable under antibiotic selection pressure. Without more detailed analyses, it is not possible to accurately determine which transmission route dominated, only that all of these possibilities exist.

As for the differences between genotype-predicted/expected and phenotypic resistance, it must be pointed out that the accuracy of such algorithms decreases with the number of resistance and virulence genes present, which the isolates analyzed here have an overabundance of. Moreover, it is particularly difficult to infer resistance from the genotype in *P. aeruginosa*, as resistance is usually porin-mediated rather than resistance gene-mediated [50]. For example, *fosA* was detected on all *P. aeruginosa* genomes, whereas a few were phenotypically susceptible, yet, these were not the two isolates in which the gene was determined to be non-functional. Thus, despite the many advantages of molecular antibiograms [51], conventional resistance testing appears to be indispensable, especially for such highly resistant pathogens that are increasingly being screened for molecularly.

Conclusions

Hospital drains continue to play a role in the spread of multidrug-resistant pathogens, as they might form favorable niches for the emergence of multidrug-resistant bacterial populations influenced significantly due to the constant patient-driven antibiotic selection pressure. Extensive technical (e.g. rimless toilets) and hygienic measures (i.e. chemical or technical disinfection of drains), constant monitoring and strict hygiene precautions help to prevent infections, however, further technical solutions are needed to prevent biofilm formation and selection pressure at the sanitary inventory level, as antibiotics are necessary for therapy, but their metabolites in the drains cause undesirable effects.

Appendix

(See Fig. 3 and Tables 3, 4, 5).

Table 3 Plasmids detected in NDM- and OXA48-encoding *K. pneumoniae* isolates by PlasmidFinder-2.0

Plasmid	CU0071	Others	CNK1	CNK2	CNK3	CNK4	CNK5	CNK6	CNK7	CNK8	CNK9	CNK10
IncFIB(pKPHS1)	Present	5/11	98.57	98.57	98.57		98.57	98.57	98.57	98.57		98.57
IncFIB(pQil)	Present	7/11	100	100	100		100	100	100	100		100
IncFIB(K)	Absent	6/11				100					100	
IncHI1B(pNDM-MAR)	Absent	0/11				100					100	
IncHI2	Absent	0/11							100	100		100

Numbers in cells refer to sequence identity and are colored for easier visualization (for CNK isolates: dark green for 100% sequence identity, light green for 98.57% sequence identity; for CU0071 dark green for presence, grey for absence of the plasmid; for others: light green for the presence of the plasmid in some of the isolates, grey for the absence in all). The closely related environmental isolates (others) and CU0071 in particular [17] are included in the table to visualize shared plasmids. The “others” column refers to how many of the “other” environmental isolates carried the respective plasmid

Table 4 Antibiotic resistance genes detected on VIM-encoding *P. aeruginosa* genomes by the AMRFinder

	1	2	3	4	5	6	7	8	9	10	11	12	13	15	16	17	18	19	23	24	25	27
<i>aac(3)-Id</i>	x		x			x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>aac(6')-29a</i>		x																				
<i>aac(6')-29b</i>		x			x																	
<i>aac(6')-Ib</i>				x																		
<i>aac(6')-Ib'</i>				x																		
<i>aac(6')-Ib4</i>																		x				
<i>aac(6')-II</i>	x		x			x		x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>aadA2</i>			x																			
<i>aadA6</i>				x														x				
<i>aph(3'')-Ib</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>aph(3')-IIb</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>aph(3')-XV</i>																		x				
<i>aph(6)-Id</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>blaGES-1</i>																		x				
<i>blaOXA</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>blaOXA-395</i>		x			x																	
<i>blaOXA-4</i>			x																			
<i>blaOXA-486</i>			x																			
<i>blaOXA-488</i>				x														x				
<i>blaPDC-3</i>		x	x		x																	
<i>blaPDC-35</i>				x														x				
<i>blaPDC-38</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>blaVIM-2</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		x		x	x
<i>blaVIM-6</i>																					x	
<i>catB7</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>chrA</i>		x			x																	
<i>cmlA6</i>			x																			
<i>crpP</i>	x	x			x	x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>dfpB5</i>	x		x			x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>floR2</i>			x															x				

Table 4 (continued)

<i>fosA</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>gyrA_T83I</i>	x	x	x	x	x	x	x	x	x	x		x	x	x	x	x	x	x	x	x	x	x
<i>hdeD-GI</i>		x		x	x																	
<i>kefB-GI</i>				x																		
<i>merA</i>		x	x	x	x													x		x		
<i>merB</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>merD</i>			x	x														x		x		
<i>merE</i>	x		x	x		x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>merP</i>		x	x	x	x													x		x		
<i>merR</i>		x	x	x	x													x		x		
<i>merT</i>		x	x	x	x													x		x		
<i>mexA</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>mexE</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>mexX</i>	x	x	x		x	x	x	x	x	x	x	x		x	x		x	x				
<i>parC_S87L</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
<i>qacEdelta1</i>		x	x	x	x													x		x		
<i>shsP</i>		x		x	x																	
<i>sul1</i>	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		x	x
<i>sul2</i>	x					x	x	x	x	x	x	x	x	x	x	x	x		x	x	x	x
<i>tet(G)</i>			x															x				
<i>trxLHR</i>		x		x	x																	
<i>yfdX1</i>		x		x	x																	
<i>yfdX2</i>		x		x	x																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	15	16	17	18	19	23	24	25	27

Isolates are colored according to isolate sequence type as in previous tables and figures

Table 5 Antibiotic resistance genes detected on NDM- and OXA48-encoding *K. pneumoniae* genomes by the AMRFinder

	CNK1	CNK2	CNK3	CNK4	CNK5	CNK6	CNK7	CNK8	CNK9	CNK10
<i>aac(3)-IId</i>				x					x	
<i>aac(3)-Ile</i>	x	x	x		x	x	x	x		x
<i>aac(6')-Ib-cr5</i>	x	x		x	x	x	x	x	x	x
<i>aadA1</i>							x	x		x
<i>aadA2</i>				x			x	x	x	x
<i>aph(3')-Ia</i>							x	x		x
<i>aph(3')-VI</i>				x					x	
<i>aph(6)-Id</i>							x	x		x
<i>armA</i>				x					x	
<i>arsA</i>				x					x	
<i>arsB</i>				x					x	
<i>arsD</i>				x					x	
<i>arsR</i>				x					x	
<i>blaCTX-M-15</i>	x	x		x	x	x	x	x	x	x
<i>blaNDM-1</i>	x	x	x	x	x		x	x	x	x
<i>blaOXA</i>				x						
<i>blaOXA-1</i>	x	x			x	x	x	x	x	x
<i>blaOXA-48</i>	x	x	x	x	x	x	x	x	x	x
<i>blaSHV</i>	x	x	x		x	x	x	x		x
<i>blaSHV-28</i>				x					x	
<i>blaTEM-1</i>	x	x	x		x		x	x		x
<i>ble</i>	x	x	x	x	x		x	x	x	x
<i>catA1</i>				x					x	
<i>catB3</i>	x	x		x	x	x	x	x	x	x
<i>dfpA1</i>	x	x	x	x	x	x	x	x	x	x
<i>dfpA12</i>				x			x	x	x	x
<i>emrD</i>	x	x	x	x	x	x	x	x	x	x
<i>fosA</i>	x	x	x	x	x	x	x	x	x	x
<i>gyrA_D87G</i>				x					x	
<i>gyrA_S83I</i>	x	x	x		x	x	x	x		x
<i>gyrA_S83Y</i>				x					x	
<i>hsp20</i>				x					x	
<i>merA</i>				x					x	
<i>merD</i>				x					x	
<i>merE</i>				x					x	
<i>merR</i>				x					x	
<i>merT</i>				x					x	
<i>mph(A)</i>							x	x		x
<i>mph(E)</i>				x					x	
<i>msr(E)</i>				x					x	

Table 5 (continued)

<i>ompK36_D135DGD</i>	x	x	x	x	x	x	x	x	x	x
<i>oqxA</i>	x	x	x	x	x	x	x	x	x	x
<i>oqxB</i>	x	x	x	x	x	x	x	x	x	x
<i>parC_S80I</i>	x	x	x	x	x	x	x	x	x	x
<i>pcoA</i>				x			x	x	x	x
<i>pcoB</i>				x			x	x	x	x
<i>pcoC</i>				x			x	x	x	x
<i>pcoD</i>				x			x	x	x	x
<i>pcoE</i>				x			x	x	x	x
<i>pcoR</i>				x			x	x	x	x
<i>pcoS</i>				x			x	x	x	x
<i>phoQ_R16C</i>				x					x	
<i>pmrB_R256G</i>	x	x	x		x	x	x	x		x
<i>qacE</i>								x		x
<i>qacEdelta1</i>	x	x	x	x	x	x	x	x	x	x
<i>qacL</i>							x	x		x
<i>qnrB1</i>	x	x	x		x	x	x	x		x
<i>sat2</i>				x					x	
<i>silA</i>				x			x	x	x	x
<i>silB</i>				x			x	x	x	x
<i>silC</i>				x			x	x	x	x
<i>silE</i>				x			x	x	x	x
<i>silF</i>				x			x	x	x	x
<i>silP</i>				x			x	x	x	x
<i>silR</i>				x			x	x	x	x
<i>silS</i>				x			x	x	x	x
<i>sul1</i>	x	x	x	x	x	x	x	x	x	x
<i>sul3</i>							x	x		x
<i>terB</i>				x					x	
<i>terC</i>				x					x	
<i>terD</i>				x			x	x	x	x
<i>terE</i>				x					x	
<i>terW</i>							x	x		x
<i>terZ</i>							x	x		x
<i>tet(A)</i>	x	x	x	x	x	x	x	x	x	x
<i>tet(M)</i>							x	x		x
<i>ybtP</i>	x	x	x	x	x	x	x	x	x	x
<i>ybtQ</i>	x	x	x	x	x	x	x	x	x	x
	CNK1	CNK2	CNK3	CNK4	CNK5	CNK6	CNK7	CNK8	CNK9	CNK10

Isolates are colored according to isolate sequence type as in previous tables and figures

Acknowledgements

The authors have no acknowledgments to make.

Author contributions

CN and GB contributed to study design. CN, ES, TD, CB, NK, JB, KA, KS, TH, GF, PB and MP contributed to data collection. CN, MN, OS, TD, CB, NK, JB, KA, SE and GB contributed to data analysis. CN, ES, MN, OS, CB, KS, SE, NTM, GB, and MP contributed to data interpretation, CN, ES, MN, OS, CB, KA and GB contributed to the literature search. CN, ES, MN, OS, TD, CB, JB, KS, SE, NTM, GB and MP contributed to writing of the report. All authors reviewed and approved the final version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. This research received no external funding.

Availability of data and materials

All data relevant to the study are included in the article or uploaded as Appendix. Raw reads have been uploaded to the Sequence Read Archive (SRA); accession PRJNA845217.

Declarations**Ethics approval and consent to participate**

The ethics committee of the University Hospital Bonn confirmed that no ethics approval was required for this study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. The authors received no external financial support for the research, authorship, and publication of this article.

Author details

¹Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. ²Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany. ³Bioinformatics and Systems Biology, Justus Liebig University Giessen, Giessen, Germany. ⁴Department of Microbiology and Hospital Hygiene, Bundeswehr Central Hospital Koblenz, Koblenz, Germany. ⁵Department of Oncology, Hematology, and Rheumatology, University Hospital Bonn, Bonn, Germany.

Received: 28 November 2022 Accepted: 29 March 2023

Published online: 15 April 2023

References

- Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health. *Water*. 2020;12(12):3313.
- Lomazzi M, Moore M, Johnson A, Balasegaram M, Borisch B. Antimicrobial resistance—moving forward? *BMC Public Health*. 2019;19(1):1–6.
- Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: a global emerging threat to public health systems. *Crit Rev Food Sci Nutr*. 2017;57(13):2857–76.
- Nikaido H. Multidrug resistance in bacteria. *Annu Rev Biochem*. 2009;78:119–46.
- Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis*. 2017;215(suppl 1):S28.
- Marti E, Jofre J, Balcazar JL. Prevalence of antibiotic resistance genes and bacterial community composition in a river influenced by a wastewater treatment plant. *PLoS ONE*. 2013;8(10):e78906.
- Baquero F, Martínez JL, Cantón R. Antibiotics and antibiotic resistance in water environments. *Curr Opin Biotechnol*. 2008;19(3):260–5.
- Pikkemaat MG, Yassin H, Fels-Klerx HJ, Berendsen BJA. Antibiotic residues and resistance in the environment (No. 2016.009). RIKILT Wageningen UR. 2016.
- Brink AJ. Epidemiology of carbapenem-resistant gram-negative infections globally. *Curr Opin Infect Dis*. 2019;32(6):609–16.
- Diene SM, Rolain JM. Carbapenemase genes and genetic platforms in gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. *Clin Microbiol Infect*. 2014;20(9):831–8.
- Voigt AM, Faerber HA, Wilbring G, Skutlarek D, Felder C, Mahn R, Wolf D, Brossart P, Hornung T, Engelhart S, Exner M, Schmithausen RM. The occurrence of antimicrobial substances in toilet, sink and shower drainpipes of clinical units: a neglected source of antibiotic residues. *Int J Hyg Environ Health*. 2019;222(3):455–67. <https://doi.org/10.1016/j.ijheh.2018.12.013>. (Epub 2019 Jan 6 PMID: 30622005).
- Schuster D, Axtmann K, Holstein N, Felder C, Voigt A, Färber H, Bierbaum G. Antibiotic concentrations in raw hospital wastewater surpass minimal selective and minimum inhibitory concentrations of resistant Acinetobacter baylyi strains. *Environ Microbiol*. 2022;24:5721.
- Sib E, Lenz-Plet F, Barabasch V, Klanke U, Savin M, Hembach N, Schallenberg A, Kehl K, Albert C, Gajdiss M, Zacharias N, Müller H, Schmithausen RM, Exner M, Kreyenschmidt J, Schreiber C, Schwartz T, Parčina M, Bierbaum G. Bacteria isolated from hospital, municipal and slaughterhouse wastewaters show characteristic, different resistance profiles. *Sci Total Environ*. 2020;746:140894. <https://doi.org/10.1016/j.scitotenv.2020.140894>.
- Lépesová K, Olejníková P, Mackulak T, Cverenkárová K, Krahulcová M, Bírošová L. Hospital wastewater-important source of multidrug resistant coliform bacteria with ESBL-production. *Int J Environ Res Public Health*. 2020;17(21):7827. <https://doi.org/10.3390/ijerph17217827>. PMID:33114613;PMCID:PMC7663260.
- Effah CY, Sun T, Liu S, Wu Y. Klebsiella pneumoniae: an increasing threat to public health. *Ann Clin Microbiol Antimicrob*. 2020;19(1):1–9.
- Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa—mechanisms, epidemiology and evolution. *Drug Resist Updates*. 2019;44:100640.
- Kehl K, Schallenberg A, Szekat C, Albert C, Sib E, Exner M, Bierbaum G. Dissemination of carbapenem resistant bacteria from hospital wastewater into the environment. *Sci Total Environ*. 2022;806:151339.
- Peirano G, Chen L, Kreiswirth BN, Pitout JD. Emerging antimicrobial-resistant high-risk Klebsiella pneumoniae clones ST307 and ST147. *Antimicrob Agents Chemother*. 2020;64(10):e01148-e1220.
- Damjanova I, Toth A, Paszti J, Hajbel-Vékony G, Jakab M, Berta J, Füzi M. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type β -lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005—the new ‘MRSAs’? *J Antimicrob Chemother*. 2008;62(5):978–85.
- Coelho A, Mirelis B, Alonso-Tarrés C, Larrosa MN, Miró E, Abad RC, González-López JJ. Detection of three stable genetic clones of CTX-M-15-producing Klebsiella pneumoniae in the Barcelona metropolitan area Spain. *J Antimicrob Chemother*. 2009;64(4):862–4.
- Wang MG, Liu ZY, Liao XP, Sun RY, Li RB, Liu Y, Zhang RM. Retrospective data insight into the global distribution of carbapenemase-producing Pseudomonas aeruginosa. *Antibiotics*. 2021;10(5):548.
- Pelegrin AC, Saharman YR, Griffon A, Palmieri M, Mirande C, Karuniawati A, Severin JA. High-risk international clones of carbapenem-nonsusceptible pseudomonas aeruginosa endemic to Indonesian intensive care units: impact of a multifaceted infection control intervention analyzed at the genomic level. *MBio*. 2019;10(6):e02384-e2419.
- Zowawi HM, Syrmis MW, Kidd TJ, Balkhy HH, Walsh TR, Al Johani SM, Paterson DL. Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf cooperation council states: dominance of high-risk clones in the region. *J Med Microbiol*. 2018;67(6):846–53.
- Sib E, Voigt AM, Wilbring G, Schreiber C, Faerber HA, Skutlarek D, Schmithausen RM. Antibiotic resistant bacteria and resistance genes in biofilms in clinical wastewater networks. *Int J Hyg Environ Health*. 2019;222(4):655–62.
- Bortolaia V, Kaas RF, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo AR, Florensa AR, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf I, Nykäsenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. ResFinder 4.0

- for predictions of phenotypes from genotypes. *J Antimicrob Chemother.* 2020;75(12):3491–500.
26. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J Antimicrob Chemother.* 2020;72(10):2764–8.
 27. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. BLAST+: architecture and applications. *BMC Bioinf.* 2009;10(1):421.
 28. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Aarestrup FM, Hasman H. PlasmidFinder and pMLST: in silico detection and typing of plasmids. *Antimicrob Agents Chemother.* 2014;58(7):3895–903.
 29. Feldgarden M, Brover V, Fedorov B, Haft DH, Prasad AB, Klimke W. Curation of the AMRFinderPlus databases: applications, functionality and impact. *Microb Genom.* 2022. <https://doi.org/10.1099/mgen.0.000832>.
 30. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Sci Rep.* 2021;11(1):12728. <https://doi.org/10.1038/s41598-021-91456-0>.
 31. Schwengers O, Hoek A, Fritzenwanker M, Falgenhauer L, Hain T, Chakraborty T, et al. ASA3P: an automatic and scalable pipeline for the assembly, annotation and higher-level analysis of closely related bacterial isolates. *PLoS Comput Biol.* 2020;16(3):e1007134. <https://doi.org/10.1371/journal.pcbi.1007134>.
 32. Jünemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, Mellmann A, Goesmann A, von Haeseler A, Stoye J, Harmsen D. Updating benchtop sequencing performance comparison. *Nat Biotechnol.* 2013;31(4):294–6. <https://doi.org/10.1038/nbt.2522>.
 33. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat Rev Microbiol.* 2020;18:344–59.
 34. Heireman L, Hamerlinck H, Vandendriessche S, Boelens J, Coorevits L, De Brabandere E, Leroux-Roels I. Toilet drain water as a potential source of hospital room-to-room transmission of carbapenemase-producing *Klebsiella pneumoniae*. *J Hosp Infect.* 2020;106(2):232–9.
 35. Abney SE, Bright KR, McKinney J, Ijaz MK, Gerba CP. Toilet hygiene—review and research needs. *J Appl Microbiol.* 2021;131(6):2705–14.
 36. Walker JT, Jhutti A, Parks S, Willis C, Copley V, Turton JF, Bennett AM. Investigation of healthcare-acquired infections associated with *Pseudomonas aeruginosa* biofilms in taps in neonatal units in Northern Ireland. *J Hosp Infect.* 2014;86(1):16–23.
 37. Gona F, Comandatore F, Battaglia S, Piazza A, Trovato A, Lorenzin G, Cichero P, Biancardi A, Nizzero P, Moro M, Cirillo DM. Comparison of core-genome MLST, coreSNP and PFGE methods for *Klebsiella pneumoniae* cluster analysis. *Microb Genom.* 2020;6(4):e000347. <https://doi.org/10.1099/mgen.0.000347>.
 38. Tönnies H, Prior K, Harmsen D, Mellmann A. Establishment and evaluation of a core genome multilocus sequence typing scheme for whole-genome sequence-based typing of *Pseudomonas aeruginosa*. *J Clin Microbiol.* 2021;59(3):e01987–e2020.
 39. Neidhöfer C, Sib E, Benhsain AH, Mutschnik-Raab C, Schwabe A, Wollkopf A, Parčina M. Examining different analysis protocols targeting hospital sanitary facility microbiomes. *Microorganisms.* 2023;11(1):185.
 40. Casals-Pascual C, Vergara A, Vila J. Intestinal microbiota and antibiotic resistance: perspectives and solutions. *Hum Microbiome J.* 2018;9:11–5.
 41. Neidhöfer C, Buechler C, Neidhöfer G, Bierbaum G, Hannel I, Hoerauf A, Parčina M. Global distribution patterns of carbapenemase-encoding bacteria in a new light: clues on a role for ethnicity. *Front Cell Infect Microbiol.* 2021. <https://doi.org/10.3389/fcimb.2021.659753>.
 42. Wang Y, Wang J, Wang R, Cai Y. Resistance to ceftazidime–avibactam and underlying mechanisms. *J Glob Antimicrob Resist.* 2020;22:18–27.
 43. Petrosillo N, Taglietti F, Granata G. Treatment options for colistin resistant *Klebsiella pneumoniae*: present and future. *J Clin Med.* 2019;8(7):934.
 44. Wang X, Liu Y, Qi X, Wang R, Jin L, Zhao M, Zhang Y, Wang Q, Chen H, Wang H. Molecular epidemiology of colistin-resistant Enterobacteriaceae in inpatient and avian isolates from China: high prevalence of mcr-negative *Klebsiella pneumoniae*. *Int J Antimicrob Agents.* 2017;50(4):536–41. <https://doi.org/10.1016/j.ijantimicag.2017.05.009>. (Epub 2017 Jun 28 PMID: 28668693).
 45. Cheng YH, Lin TL, Pan YJ, Wang YP, Lin YT, Wang JT. Colistin resistance mechanisms in *Klebsiella pneumoniae* strains from Taiwan. *Antimicrob Agents Chemother.* 2015;59(5):2909–13. <https://doi.org/10.1128/AAC.04763-14>.
 46. Miglitori LB, Leaden L, de Sales RO, Correa NP, Marins MM, Koga PCM, Toniolo ADR, de Menezes FG, Martino MDV, Mingorance J, Severino P. The gastrointestinal load of carbapenem-resistant enterobacteriaceae is associated with the transition from colonization to infection by *Klebsiella pneumoniae* isolates harboring the blaKPC gene. *Front Cell Infect Microbiol.* 2022;12:928578. <https://doi.org/10.3389/fcimb.2022.928578>.
 47. Isler B, Özer B, Çınar G, et al. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant *Klebsiella* spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. *Eur J Clin Microbiol Infect Dis.* 2022;41:841–7. <https://doi.org/10.1007/s10096-022-04425-4>.
 48. KRINKO-Empfehlung. Anforderungen der Hygiene an abwasserführende Systeme in medizinischen Einrichtungen. *Bundesgesundheitsbl* 2020;63:484–501
 49. de Jonge E, de Boer MGJ, van Essen EHR, Dogterom-Ballering HCM, Veldkamp KE. Effects of a disinfection device on colonization of sink drains and patients during a prolonged outbreak of multidrug-resistant *Pseudomonas aeruginosa* in an intensive care unit. *J Hosp Infect.* 2019;102(1):70–4.
 50. Moore NM, Flaws ML. Antimicrobial resistance mechanisms in *Pseudomonas aeruginosa*. *Clin Lab Sci.* 2011;24(1):47.
 51. Arena F, Giani T, Pollini S, Viaggi B, Pecile P, Rossolini GM. Molecular antibiogram in diagnostic clinical microbiology: advantages and challenges. *Future Microbiol.* 2017;12(5):361–4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

